Company Overview of APT Pharmaceuticals, Inc.
APT Pharmaceuticals, Inc. develops cyclosporine inhalation solution for the prevention of chronic rejection in lung transplantation. The company's cyclosporine inhalation solution is an inhaled formulation of cyclosporine A, an oral medication is used to prevent rejection in solid organ transplant recipients. The company was founded in 1999 and is based in Burlingame, California.
700 Airport Boulevard
Burlingame, CA 94010
Founded in 1999
Key Executives for APT Pharmaceuticals, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact APT Pharmaceuticals, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.